Summary
Vertex Pharmaceuticals Incorporated (VRTX) announced on December 15, 2006, that its partner GlaxoSmithKline (GSK) has decided to discontinue the clinical development of brecanavir (VX-385), an investigational HIV protease inhibitor. Brecanavir had reached Phase 2 clinical trials and was part of the long-standing HIV Protease Collaboration between Vertex and GSK, which also includes the marketed drugs Agenerase and Lexiva. GSK's decision stems from perceived difficulties in developing an appropriate formulation for brecanavir. While this halts the development of a specific pipeline asset, it is important to note that GSK's decision does not impact the ongoing marketing relationship for Lexiva under the same collaboration. Investors should monitor the impact of this discontinued development on Vertex's pipeline and future revenue expectations, though the existing revenue streams from Lexiva remain unaffected.
Key Highlights
- 1GlaxoSmithKline (GSK) has ceased development of brecanavir (VX-385), an investigational HIV protease inhibitor.
- 2Brecanavir had advanced to Phase 2 clinical trials.
- 3The decision to halt development is attributed to formulation challenges identified by GSK.
- 4Brecanavir was part of the HIV Protease Collaboration between Vertex and GSK, initiated in 1993.
- 5The discontinuation of brecanavir development does not affect the marketing of Lexiva under the same collaboration.
- 6Vertex's existing marketed HIV drugs, Agenerase and Lexiva, continue to be part of the collaboration.